Research advances in adverse drug reactions and their management in targeted therapy for driver gene-positive advanced non-small cell lung cancer
10.12173/j.issn.1005-0698.202507079
- VernacularTitle:驱动基因阳性晚期非小细胞肺癌靶向治疗的不良反应及其管理研究进展
- Author:
Jiameng FAN
1
;
Lei PAN
Author Information
1. 西安医学院研究生工作部(西安 710021);空军军医大学唐都医院呼吸与危重症医学科(西安 710038)
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
Target therapy;
Adverse drug reactions;
Symptom management;
Biomarker
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(11):1320-1329
- CountryChina
- Language:Chinese
-
Abstract:
Molecular targeted therapy for non-small cell lung cancer has significantly improved clinical outcomes in patients with driver gene-positive tumors.Nevertheless,treatment-related adverse drug reactions(ADRs)present challenges to patients'quality of life and treatment adherence.Given the broad clinical utilization of various targeted agents,it is imperative to comprehensively characterize and standardize the management of these ADRs.This review systematically synthesizes the common and unique spectra of ADRs associated with inhibitors targeting multiple pathways,including the epidermal growth factor receptor,encompassing dermatologic toxicities,diarrhea,hepatotoxicity,and interstitial lung disease.It also discusses the potential role of predictive biomarkers in identifying high-risk populations to facilitate early risk stratification.Furthermore,based on current evidence-based medicine and authoritative clinical guidelines,this work highlighted a multidisciplinary management strategy,tailored according to severity grading,which includes dose modification or treatment interruption,symptomatic and supportive care,as well as lifestyle interventions.Through a deepened understanding,proactive monitoring,and standardized management of ADRs,the aim is to maximize treatment benefits while minimizing therapy-related toxic burden.
